Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The short-chain fatty acid production pathway refers to the series of biochemical reactions carried out primarily by anaerobic bacteria in the human large intestine that convert indigestible dietary fibers and resistant starches into short-chain fatty acids (SCFAs), mainly acetate, propionate, and butyrate. These SCFAs are produced through several distinct microbial fermentation pathways involving different substrates such as acetyl-CoA, succinyl-CoA, 2‑oxoglutarate, and L‑lysine. The resulting SCFAs play crucial roles in host physiology including serving as energy sources for colonocytes; regulating immune responses; maintaining intestinal barrier function; influencing hormone secretion such as growth hormone via GPR41/43 activation; modulating brain function through the gut-brain axis; and potentially affecting systemic inflammation and metabolic health. Alterations in SCFA production have been implicated in various diseases including inflammatory bowel disease, obesity/metabolic syndrome, neurodegenerative conditions via altered gut-brain signaling pathways, and colorectal cancer risk modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Short-chain fatty acid production pathway.